title: Characteristics, drug combinations and dosages of primary care patients with uncontrolled ambulatory blood pressure and high medication adherence.
abstract: Most studies on the prevalence and determinants of resistant hypertension (RH) do not account for white coat hypertension, medication non-adherence, or use of suboptimal treatment dosages. We studied the characteristics, drug combinations, and dosages of patients on at least three antihypertensives of different classes who had uncontrolled blood pressure on 24-hour ambulatory blood pressure monitoring and high medication adherence measured by electronic monitoring. The data were collected as part of the baseline measures of a hypertension control trial. Of 140 monitored primary care patients, all with uncontrolled office blood pressure, 69 (49%) were on at least three antihypertensives of different classes. Of these 69, 15 (22%) were controlled on ambulatory blood pressure monitoring, 20 (29%) were uncontrolled and non-adherent, leaving only 34 (49%) adherent to their medications and having uncontrolled ambulatory hypertension (uncontrolled RH). Thirty-one (91%) of the 34 uncontrolled RH patients were prescribed a diuretic, of which 24 were on hydrochlorothiazide 25 mg. Less than half of the patients on angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, or calcium channel blocker were prescribed maximal doses of these agents. Half of the RH can be attributed to white coat effect and poor medication adherence, and all of the remaining patients were on apparently suboptimal drug combinations and/or dosages. Primary care physicians need to be educated regarding the optimal treatment of RH.
authors.affiliation: Department of Family and Community Medicine, Baylor College of Medicine, Houston, TX, USA. Electronic address: grigorya@bcm.edu.
authors.forename: Larissa
authors.initials: L
authors.lastname: Grigoryan
authors.affiliation: Department of Family and Community Medicine, Baylor College of Medicine, Houston, TX, USA.
authors.forename: Valory N
authors.initials: VN
authors.lastname: Pavlik
authors.affiliation: Department of Family and Community Medicine, Baylor College of Medicine, Houston, TX, USA.
authors.forename: David J
authors.initials: DJ
authors.lastname: Hyman
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D018660:Blood Pressure Monitoring, Ambulatory; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D011320:Primary Health Care / Q000379:methods*; D059466:White Coat Hypertension / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D004232:Diuretics
keywords: Resistant hypertension; drug dosage; electronic monitoring; medication adherence; white-coat hypertension
references.citation: J Am Coll Cardiol. 2011 Feb 1;57(5):590-600
references.pmid: 21272751
references.citation: J Clin Hypertens (Greenwich). 2013 Feb;15(2):107-11
references.pmid: 23339728
references.citation: Circulation. 2008 Jun 24;117(25):e510-26
references.pmid: 18574054
references.citation: Am J Hypertens. 2008 Oct;21(10):1137-43
references.pmid: 18654123
references.citation: J Hypertens. 2001 Nov;19(11):2063-70
references.pmid: 11677373
references.citation: Hypertension. 2009 Sep;54(3):524-9
references.pmid: 19581506
references.citation: Med Care. 1999 Sep;37(9):846-57
references.pmid: 10493464
references.citation: Cochrane Database Syst Rev. 2012 Aug 15;(8):CD002003
references.pmid: 22895924
references.citation: Circulation. 2011 Aug 30;124(9):1046-58
references.pmid: 21824920
references.citation: J Hum Hypertens. 2011 Feb;25(2):137-40
references.pmid: 21124342
references.citation: Hypertension. 2011 May;57(5):898-902
references.pmid: 21444835
references.citation: Clin Ther. 1997 Nov-Dec;19(6):1433-45; discussion 1424-5
references.pmid: 9444451
references.citation: Hypertension. 2011 Jun;57(6):1076-80
references.pmid: 21502568
references.citation: J Clin Hypertens (Greenwich). 2011 Jun;13(6):416-21
references.pmid: 21649841
references.citation: Curr Atheroscler Rep. 2011 Apr;13(2):147-53
references.pmid: 21207202
references.citation: Am J Hypertens. 2001 Dec;14(12):1263-9
references.pmid: 11775136
references.citation: J Hypertens. 2012 Jun;30(6):1211-6
references.pmid: 22525201
references.citation: Circulation. 2012 Apr 3;125(13):1635-42
references.pmid: 22379110
references.citation: Blood Press. 2013 Apr;22(2):65-72
references.pmid: 23035939
references.citation: J Clin Hypertens (Greenwich). 2012 Jan;14(1):7-12
references.pmid: 22235818
references.citation: Eur J Cardiovasc Prev Rehabil. 2005 Jun;12(3):243-9
references.pmid: 15942423
references.citation: Hypertension. 2011 Dec;58(6):1008-13
references.pmid: 22042809
references.citation: Drugs. 1994 Jul;48(1):16-24
references.pmid: 7525192
references.citation: J Am Coll Cardiol. 2002 Mar 6;39(5):878-85
references.pmid: 11869856
references.citation: J Clin Hypertens (Greenwich). 2012 Oct;14(10):694-700
references.pmid: 23031147
references.citation: Am J Hypertens. 2012 Jul;25(7):735-8
references.pmid: 22441507
references.citation: J Gen Intern Med. 2012 Apr;27(4):413-9
references.pmid: 22033742
references.citation: Circ Cardiovasc Qual Outcomes. 2009 May;2(3):257-63
references.pmid: 20031846
references.citation: Clin Exp Hypertens. 2013;35(6):412-7
references.pmid: 23148480